Breaking News
14 minutes ago
Simantini Singh Deo
Novo Nordisk and Aspect deepen their alliance to accelerate scalable, potentially curative cell therapies for diabetes.
Simantini Singh Deo
BrightInsight raises $13M to expand its AI-enabled platform addressing medication non-adherence across chronic diseases globally.
Simantini Singh Deo
Capricor moves forward with FDA review of Deramiocel, submitting full HOPE-3 data to address CRL with no new trials required.
Simantini Singh Deo
BrightInsight appoints new COO, SVP, and VP of Product to scale operations and accelerate digital health innovation for biopharma.
Simantini Singh Deo